National Biotechnology Research Park (Resident company)
Vacino Biotech established in July 2020 focuses on developing the products of universal vaccine and nucleic acid medicine. Dr. Jia-Ming Chang was appointed as CEO and led the research to productize the flu and COVID vaccine with the state-of-the-art universal technology and the microRNA therapeutic toward clinical application. With our self-developed AD TECH®, we designed a universal vaccine for COVID-19. In addition, we also developed R-MOD® tech to improve the stability, deliverability, and targetability of RNA medicine for the treatment of resistant lung cancer. For QC the RNA product in manufacturing, we also hold the capability in diagnosing the levels of miRNA. In 2023, the first Vacino product will be tested in clinically.